ABT-414

Property	Information
Drug Name	ABT-414
Overview	ABT-414 is an antibody-drug conjugate currently in Phase 1 clinical trials, designed to target EGFR-overexpressing glioblastoma cells, but has not yet received FDA approval. While it shows a median progression-free survival of 6.1 months, it is associated with significant eye toxicities, particularly blurred vision, indicating a cautionary approach is necessary due to its potential high toxicity and the challenges noted in early trials.
FDA Approval	No
Used for	Targeting EGFR overexpressing glioblastoma cells
Clinical Trial Phase	Phase 1
Clinical Trial Explanation	Not specified
Common Side Effects	Eye toxicities, especially blurred vision
OS without	Not specified
OS with	Not reached at a median follow-up of 5.8 months
PFS without	Not specified
PFS with	6.1 months for all patients, 5.9 months for EGFR amplified patients
Usefulness Rating	2
Usefulness Explanation	Not specified
Toxicity Level	4
Toxicity Explanation	The drug ABT-414 is in phase 1 of its clinical trials. It demonstrates a tendency towards eye toxicities, especially causing blurred vision. This is an indication of potentially high toxicity. However, due to small sample size and other variables in the study, the evaluations should be taken with caution. It is advised to expect a higher level of toxicity until tested further in next clinical trial phases.

Notes: ABT-414, an antibody-drug conjugate, selectively targets EGFR expressing tumor cells with minimal effects on healthy tissue. The phase 1 study highlighted challenges such as variable doses, study drug discontinuations due to toxicities, and small sample size, advising caution in evaluating efficacy parameters.

From Ben Williams Book: Not specified

Loading comments...